Novo Nordisk will ration starter kits of Ozempic in Europe and reduce supplies of another diabetes drug, Victoza, to prioritise producing Ozempic, which has seen a surge in demand from people using it to lose weight.
Obesity drug maker Novo Nordisk will spend $6 billion to boost production in Denmark, although its CEO warned the industry was far from being able to meet global demand.
A decades-old federal program that offers doctors incentives to practice in disadvantaged communities has had little effect on physician density or patient mortality.
Most of the new capacity will be dedicated to manufacturing active pharmaceutical ingredients, including for Wegovy and Ozempic, used to treat diabetes and obesity.
The U.S. has been experiencing its worst year for drug shortages in a decade, with Sanofi and AstraZeneca's new RSV shot for infants as the latest high-profile example.